UBS AM
CALA

UBS AM’s Calithera Biosciences, Inc CALA Stock Holding History

UBS AM’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,195
Closed -$155K – 2792
2021
Q1 		$155K Buy
3,195
+1,350
+73% +$78.6K ﹤0.01% 2579
2020
Q4 		$181K Hold
1,845
– – ﹤0.01% 2517
2020
Q3 		$127K Buy
1,845
+40
+2% +$3.49K ﹤0.01% 2450
2020
Q2 		$191K Buy
+1,805
New +$214K ﹤0.01% 2397
2018
Q2 		– Sell
-550
Closed -$69.3K – 2813
2018
Q1 		$69.3K Hold
550
– – ﹤0.01% 2478
2017
Q4 		$91.8K Buy
+550
New +$141K ﹤0.01% 2409

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS AM's CALA Position: Q2 2021 in Review

UBS AM sold out of Calithera Biosciences, Inc (CALA) in Q2 2021, closing a stake of 3,195 shares — an estimated $155K sold.

UBS AM first reported a position in CALA in Q4 2017 and held it in 6 quarters. The position peaked at $191K in Q2 2020. 76 funds tracked by Wall St. Rank hold CALA as of Q2 2021.

  • UBS AM reported no remaining Calithera Biosciences, Inc position as of Q2 2021 after selling out during the quarter.
  • UBS AM sold 3,195 Calithera Biosciences, Inc shares in Q2 2021, an estimated $155K.
  • UBS AM first reported a position in Calithera Biosciences, Inc in Q4 2017 and held it in 6 quarters.
  • UBS AM's Calithera Biosciences, Inc position peaked at $191K in Q2 2020.
  • 76 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2021.

Based on UBS AM's 13F filing for Q2 2021, filed 16 Aug 2021.